poles of the parenchymal cells as assessed by immunohisto- 1 To whom correspondence should be addressed chemical analyses (8) .
Email: olivier.fardel@univ-rennes1.fr Hepatic formation of many compounds considered as Expression of the canalicular multispecific organic anion cMOAT substrates, i.e. glutathione or glucuronate conjugates transporter (cMOAT), an efflux pump involved in biliary of xenobiotics, is mediated at least in part by phase II drug secretion of xenobiotics, was investigated in rat hepatocytes metabolizing enzymes such as glutathione S-transferases (GST) exposed to the chemopreventive agent oltipraz. Northern and UDP-glucuronosyl transferases (9) . Interestingly, the blotting indicated that this compound increased cMOAT expression levels of these detoxifying enzymes are well-known mRNA levels in primary cultured hepatocytes. Such an to be regulated in response to treatment with various chemicals induction of cMOAT transcripts was demonstrated to be (10) . In particular, oltipraz, a synthetic derivative of the plant dose-dependent and started as early as 4 h treatment; in product 1,2-dithiole-3-thione originally developed as an antiaddition, western blotting showed increased levels of schistosomal compound, has been demonstrated to increase 190 kDa cMOAT in oltipraz-treated primary rat hepatoexpression of conjugating enzymes such as GST A1/2 and cytes when compared with their untreated counterparts.
GST P1 (11, 12) . Such an effect on detoxication enzymes is In contrast, administration of oltipraz to rats failed to thought to result in enhanced metabolic inactivation of chemical enhance hepatic cMOAT mRNA and protein amounts carcinogens and therefore has been postulated to account, at whereas it was found to induce liver expression of glutaleast in part, for the well-known chemopreventive properties thione S-transferase P1, a well-known oltipraz-regulated of oltipraz towards chemical carcinogenesis (13) . Whether this drug metabolizing enzyme. These data therefore suggest compound may also alter hepatic levels of drug transporters, that cMOAT up-regulation occurring in rat hepatocytes in in particular those of cMOAT, remains, however, unknown, response to oltipraz may be restricted to in vitro situations but may be relevant to determine since cMOAT may mediate and is therefore unlikely to be directly involved in the the secretion into the bile of many compounds metabolized in vivo chemopreventive properties of oltipraz.
by oltipraz-induced detoxifying enzymes. The present study was therefore designed to analyse the expression of cMOAT in response to treatment with oltipraz. This work was conducted using primary rat hepatocyte cultures, which have been proThe canalicular multispecific organic anion transporter posed as suitable models for investigating the effects of (cMOAT), also termed multidrug resistance-associated protein chemopreventive agents on hepatic detoxication pathways (MRP2) or canalicular multidrug resistance-associated protein (11, 14) , and using oltipraz-treated rats. (cMRP), is a membrane transporter predominantly found at Hepatocytes were isolated by two-step perfusion of the liver the biliary pole of hepatocytes (1,2). This 190 kDa protein of male Sprague-Dawley or Wistar rats (weighing 180-200 g) mediates the passage of various types of organic anions, with a collagenase solution as previously described (15) . Cells including glucuronate, sulphate and glutathione conjugates, were then plated at a density of 10 5 cells/cm 2 in plastic dishes from hepatocytes into the bile (3). The hepatobiliary secretion in Williams' medium supplemented with 0.2 mg/ml bovine of such compounds is therefore strongly reduced in mutant rat serum albumin, 10 µg/ml bovine insulin and 10% strains lacking cMOAT expression such as the TR -rat and the (v/v) fetal calf serum. After a 4 h cell attachment period, the EHBR rat (1,2,4). Similarly, a deficiency in human cMOAT medium was discarded and replaced by serum-free Williams' expression due to a mutation in the gene causes decreased medium containing 100 nM dexamethasone. Oltipraz, dissolved biliary excretion of bilirubin glucuronides, resulting in hereditin dimethylsulphoxide, was added with the latter medium. ary conjugated hyperbilirubinemia, known as Dubin-Johnson Control cultures received the same concentration of solvent, syndrome (5).
which did not exceed 0.2% (v/v). In agreement with previous cMOAT belongs to the superfamily of ATP-binding cassette data (11) , oltipraz, at the concentrations used, was not found transporters that comprises other drug efflux pumps such as to have any obvious cytotoxic effects towards hepatocytes as the 170 kDa P-glycoprotein (P-gp) and the 190 kDa multidrug assessed by careful light microscopic examination of the resistance-associated protein (MRP, also known as MRP1) (1).
cultures. MRP, initially described in tumour cell lines exhibiting a For animal treatment, male Wistar rats (weighing 180-200 g) were fed a diet with oltipraz added at a final concentration of were killed and livers were immediately removed and kept P-gp, P-glycoprotein; RT-PCR, reverse transcription-polymerase chain reaction.
at -80°C until use.
For northern blotting, total RNA was extracted from cells or liver fragments using the guanidium thiocyanate/cesium chloride method (16) as modified by Raymondjean et al. (17) . Total RNA (10 µg) was then subjected to electrophoresis in a denaturing formaldehyde-agarose gel and transferred onto Hybond-N ϩ sheets (Amersham, Les Ulis, France). The membrane sheets were hybridized overnight at 65°C with 32 P-labelled probes; cMOAT mRNAs were detected with a 860 bp cMOAT cDNA fragment (18) whereas GST P1 mRNAs were analysed with the pGSTr7 cDNA probe (19) . After hybridization, the sheets were washed, dried and autoradiographed at -80°C. Equal RNA loading onto the gel and the efficiency of transfer were checked by rehybridizing the blots with an 18S rRNA probe (20) .
For reverse transcription-polymerase chain reaction (RT-PCR) assays, total RNA (0.5 µg) was first reverse transcribed using 200 U of Moloney murine leukemia virus transcriptase (Gibco BRL, Cergy-Pontoise, France). An amount of cDNA Western blot analyses were performed using crude membranes prepared from primary hepatocytes by differential centrifugation as reported by Germann et al. (22) and using altered in response to oltipraz treatment. Such cMOAT mRNAs probably represent alternative mRNA splicing variants with whole cell lysates of liver fragments. Protein samples were separated on 7.5% (for cMOAT analysis) or 12.5% (for different 3Ј-untranslated region lengths (24) . The up-regulation of cMOAT mRNA levels evident in GST P1 analysis) polyacrylamide gels and electrophoretically transferred to a nitrocellulose sheet. The sheets were then oltipraz-treated primary hepatocytes in northern blotting experiments was also demonstrated using RT-PCR assays with blocked for 2 h with Tris-buffered saline containing 3% bovine serum albumin and 1% milk. Polyclonal anti-cMOAT specific cMOAT primers (data not shown). In addition, such regulation, described in primary cultures of Sprague-Dawley antibodies EAG15 (2) (kindly provided by Dr D.Keppler, Deutsches Krebsforschungszentrum, Heidelberg, Germany) or rat hepatocytes, was also found to occur in cultured hepatocytes obtained from Wistar rats and exposed to 50 µM oltipraz for RM2 (directed against the C-terminal sequence of rat cMOAT) and polyclonal anti-GST P1 antibody (Biotrin, Dublin, Ireland) 48 h (data not shown). These results therefore suggest that isolated hepatocytes obtained from different rat strains respond were then applied to the membranes for 1 h at room temperature. After washing, the blots were incubated with peroxidaseto oltipraz treatment in a similar manner with respect to cMOAT expression. In contrast, regulation of P-gp levels in conjugated anti-rabbit antibody (Valbiotech, Evry, France) and were further developed by chemiluminescence using the primary hepatocytes exposed to 2-acetylaminofluorene has been shown to be dependent on the rat strain used for Amersham ECL detection system. Alkaline phosphatase activity in crude membrane fractions preparation of the liver cells; especially, primary SpragueDawley rat hepatocytes, unlike Wistar hepatocytes, were found was measured spectrophotometrically at 410 nm using a standard method as previously described (23) .
not to be responsive to 2-acetylaminofluorene (25).
To determine whether the increase in cMOAT mRNA in Northern blot analysis showed that oltipraz induced cMOAT mRNA expression in primary Sprague-Dawley rat hepatocytes oltipraz-treated cultured liver cells was associated with upregulation of cMOAT at the protein level, crude membranes in a dose-dependent manner ( Figure 1A ). An increase in cMOAT mRNA levels was evident in hepatocytes treated for were further prepared from primary Sprague-Dawley rat hepatocytes exposed to 50 µM oltipraz and from their untreated 48 h with oltipraz at 18.75 µM, whereas higher concentrations of oltipraz (50 and 100 µM) produced maximal induction of counterparts and were analysed by western blotting using the anti-cMOAT EAG15 antibody. As indicated in Figure 2 , cells cMOAT transcripts. In contrast, cultured hepatocytes exposed to a lower dose of oltipraz (12.5 µM) displayed amounts of treated with oltipraz displayed enhanced amounts of a EAG15-reactive 190 kDa protein corresponding to cMOAT. This 190 cMOAT transcripts similar to those found in their untreated counterparts. The time course of cMOAT mRNA induction by kDa protein was not detected in control blots using nonimmune rabbit serum as primary antibody instead of EAG15. 50 µM oltipraz was then analysed. As indicated in Figure 1B , up-regulation of cMOAT transcripts in primary hepatocytes
In contrast to cMOAT, alkaline phosphatase, a membrane marker enzyme, was not up-regulated by oltipraz treatment. started as soon as 4 h treatment and was maximal for longer exposures (12-48 h) to oltipraz, whereas shorter treatment Indeed, alkaline phosphatase activity measured in crude membranes prepared from oltipraz-treated hepatocytes corresponded (1 h) failed to alter cMOAT mRNA levels. As previously reported (2), several cMOAT transcripts of different sizes, to 82 Ϯ 16% of the value found in membranes obtained from untreated hepatocytes. This result suggests that the effect of especially a major one of 5.5 kb, were evident on the northern blots; their relative proportions were, however, not obviously oltipraz on cMOAT levels in primary hepatocytes is likely and protein levels were strongly enhanced in the liver of oltipraz-treated rats when compared with those observed in the liver of untreated rats ( Figure 3A and B), thus unequivocally demonstrating that the treatment that we performed was efficient in increasing expression of well-known oltiprazregulated detoxifying enzymes such as GST P1 (11). Interes- chemical to rats failed to alter hepatic P-gp expression (26). Taken together, these data suggest that caution may be required when extrapolating data from in vitro systems such as primary cultures of hepatocytes to in vivo situations, especially for regulatory pathways of hepatic drug transporters. Previous studies have, however, shown a good correlation between in vivo and in vitro data with respect to the regulation of some drug metabolizing enzymes by various xenobiotics, including chemopreventive agents (11) . The molecular mechanism by which oltipraz induces cMOAT expression in primary hepatocytes remains to be determined. Interestingly, the range of concentrations of oltipraz acting in vitro on cMOAT expression ( Figure 1A ) is close to that required for induction of oltipraz-regulated enzymes such as GST A1/2 and manganese superoxide dismutase (11, 27 ). In addition, the time course of cMOAT mRNA up-regulation in primary oltipraz-treated rat hepatocytes ( Figure 1B ) is similar to that described for GST A1/2 mRNAs (11). These data may suggest that the mechanism by which oltipraz enhances cMOAT expression in primary rat hepato- P-450 genes such as cytochrome P450 1A and 2B (30) .
In summary, our results demonstrate that, although treatment of primary rat hepatocytes with oltipraz resulted in a strong specific and not related to general up-regulation of membrane protein expression.
induction of cMOAT expression, hepatic cMOAT mRNA and protein levels, unlike those of GST P1, were not obviously cMOAT mRNA and protein levels were further analysed in the livers of oltipraz-treated Wistar rats and of their untreated altered in oltipraz-treated rats. Such results therefore suggest that the well-established in vivo chemopreventive properties counterparts. Surprisingly, both cMOAT mRNA and cMOAT protein amounts were not obviously altered in response to of oltipraz probably do not involve up-regulation of cMOAT expression in the liver. treatment with oltipraz for 4 days ( Figure 3A and B) ; shorter exposure to oltipraz (2 days) also failed to affect cMOAT
